• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

头孢地尔罗治疗由极耐药铜绿假单胞菌引起的原发性主动脉瓣心内膜炎的同情使用。

Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa.

机构信息

Department of Infectious Diseases, Guy's Hospital, Kings College London, London, United Kingdom.

Shionogi Limited, Global Clinical Development Unit, London, United Kingdom.

出版信息

Clin Infect Dis. 2019 May 17;68(11):1932-1934. doi: 10.1093/cid/ciy963.

DOI:10.1093/cid/ciy963
PMID:30418554
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6522681/
Abstract

Serious infections such as endocarditis due to extremely drug-resistance gram-negative bacteria are an increasing challenge. Here, we present successful adjunctive use of cefiderocol for a patient with persistently bacteremic healthcare-associated native aortic valve endocarditis due to an extended-spectrum beta-lactamase-positive Pseudomonas aeruginosa susceptible in vitro only to colistin, following failure of conventional therapeutic options.

摘要

严重感染，如由极耐药革兰氏阴性菌引起的心内膜炎，是一个日益严峻的挑战。在此，我们报告一例成功应用头孢地尔科治疗的病例。该患者因产超广谱β-内酰胺酶的铜绿假单胞菌引起的血培养阳性的医疗相关性自体主动脉瓣心内膜炎，在常规治疗方案失败后，对体外仅对黏菌素敏感。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31b0/6522681/36c57331c190/ciy96301.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31b0/6522681/36c57331c190/ciy96301.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31b0/6522681/36c57331c190/ciy96301.jpg

相似文献

1
Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa.头孢地尔罗治疗由极耐药铜绿假单胞菌引起的原发性主动脉瓣心内膜炎的同情使用。
Clin Infect Dis. 2019 May 17;68(11):1932-1934. doi: 10.1093/cid/ciy963.
2
Compassionate Use of Cefiderocol in the Treatment of an Intraabdominal Infection Due to Multidrug-Resistant Pseudomonas aeruginosa: A Case Report.头孢地尔在多药耐药铜绿假单胞菌引起的腹腔感染中的同情用药：一例报告。
Pharmacotherapy. 2019 Nov;39(11):1113-1118. doi: 10.1002/phar.2334. Epub 2019 Oct 22.
3
Prosthetic valve endocarditis caused by Pseudomonas aeruginosa with variable antibacterial resistance profiles: a diagnostic challenge.铜绿假单胞菌导致的人工瓣膜心内膜炎，其抗菌耐药谱存在可变型：诊断难题。
BMC Infect Dis. 2019 Jun 17;19(1):530. doi: 10.1186/s12879-019-4164-3.
4
Long-Term Compassionate Use of Cefiderocol To Treat Chronic Osteomyelitis Caused by Extensively Drug-Resistant Pseudomonas aeruginosa and Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae in a Pediatric Patient.头孢地尔长期同情用药治疗一名儿科患者由广泛耐药铜绿假单胞菌和产超广谱β-内酰胺酶肺炎克雷伯菌引起的慢性骨髓炎
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.01872-19.
5
Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data?案例评论：头孢地尔的需求显而易见，但临床数据是否支持？
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.00059-20.
6
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).头孢地尔罗的体外活性，一种铁载体头孢菌素，针对最近收集的临床相关碳青霉烯类药物不敏感的革兰氏阴性杆菌，包括丝氨酸碳青霉烯酶和金属β-内酰胺酶产生的分离株（SIDERO-WT-2014 研究）。
Int J Antimicrob Agents. 2019 Feb;53(2):177-184. doi: 10.1016/j.ijantimicag.2018.10.007. Epub 2018 Oct 26.
7
Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.头孢地尔在铜绿假单胞菌和阴沟肠杆菌染色体 AmpCβ-内酰胺酶中的稳定性和低诱导倾向。
J Antimicrob Chemother. 2018 Nov 1;73(11):3049-3052. doi: 10.1093/jac/dky317.
8
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).头孢洛扎/他唑巴坦对亚太地区（不包括中国、澳大利亚和新西兰）引起的医疗保健相关感染的耐药肠杆菌科和铜绿假单胞菌的活性：来自抗菌监测计划（2013-2015 年）的报告。
Int J Antimicrob Agents. 2018 Feb;51(2):181-189. doi: 10.1016/j.ijantimicag.2017.09.016. Epub 2017 Oct 6.
9
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.头孢地尔：一种具有抗碳青霉烯类和多药耐药革兰氏阴性杆菌活性的铁载体头孢菌素。
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
10
Ceftolozane-tazobactam for the treatment of ventilator-associated infections by colistin-resistant Pseudomonas aeruginosa.头孢洛扎-他唑巴坦用于治疗由耐黏菌素铜绿假单胞菌引起的呼吸机相关性感染。
Rev Esp Quimioter. 2017 Jun;30(3):224-228. Epub 2017 Mar 29.

引用本文的文献

1
The Evolving Landscape of Infective Endocarditis: Difficult-to-Treat Resistance Bacteria and Novel Diagnostics at the Foreground.感染性心内膜炎的演变格局：前景中的难治性耐药菌与新型诊断方法
J Clin Med. 2025 Mar 19;14(6):2087. doi: 10.3390/jcm14062087.
2
Risk Factors for Development and Mortality of Carbapenem-Resistant Bloodstream Infection in a Chinese Teaching Hospital: A Seven-Year Retrospective Study.中国一家教学医院耐碳青霉烯类血流感染发生及死亡的危险因素：一项七年回顾性研究
Infect Drug Resist. 2025 Feb 18;18:979-991. doi: 10.2147/IDR.S495240. eCollection 2025.
3
Infective endocarditis by carbapenem-resistant Gram-negative bacteria - a systematic review.

本文引用的文献

1
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.头孢地尔优于亚胺培南西司他丁钠治疗革兰氏阴性尿路病原体引起的复杂性尿路感染：一项 2 期、随机、双盲、非劣效性试验。
Lancet Infect Dis. 2018 Dec;18(12):1319-1328. doi: 10.1016/S1473-3099(18)30554-1. Epub 2018 Oct 25.
2
Pseudomonas aeruginosa sequence type 357 with VEB extended-spectrum β-lactamases in the UK: relatedness and resistance.英国具有VEB型超广谱β-内酰胺酶的357型铜绿假单胞菌：亲缘关系与耐药性
Int J Antimicrob Agents. 2018 Aug;52(2):301-302. doi: 10.1016/j.ijantimicag.2018.03.013. Epub 2018 Mar 23.
3
耐碳青霉烯革兰阴性菌所致感染性心内膜炎——一项系统评价
Germs. 2024 Jun 30;14(2):149-161. doi: 10.18683/germs.2024.1427. eCollection 2024 Jun.
4
Clinical characteristics and outcomes in pseudomonas endocarditis: a systematic review of individual cases : Systematic review of pseudomonas endocarditis.假单胞菌心内膜炎的临床特征和结局：系统评价个案报告：假单胞菌心内膜炎的系统评价。
Infection. 2024 Oct;52(5):2061-2069. doi: 10.1007/s15010-024-02311-z. Epub 2024 Jun 10.
5
New advances in management and treatment of cardiac implantable electronic devices infections.心脏植入式电子设备感染的管理和治疗新进展。
Infection. 2024 Apr;52(2):323-336. doi: 10.1007/s15010-023-02130-8. Epub 2023 Nov 24.
6
Dynamics of iron metabolism in patients with bloodstream infections: a time-course clinical study.血流感染患者铁代谢动力学：一项时间进程的临床研究。
Sci Rep. 2023 Nov 6;13(1):19143. doi: 10.1038/s41598-023-46383-7.
7
Successful use of prolonged cefiderocol monotherapy for the treatment of a complex pleural abscess caused by extensively drug-resistant (XDR) .成功使用延长的头孢地尔单药治疗广泛耐药（XDR）引起的复杂胸腔脓肿。
JAC Antimicrob Resist. 2023 Sep 6;5(5):dlad103. doi: 10.1093/jacamr/dlad103. eCollection 2023 Oct.
8
Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence.用头孢地尔治疗重症患者耐多药病原体引起的感染：证据综述
Ann Intensive Care. 2023 Jun 15;13(1):52. doi: 10.1186/s13613-023-01146-5.
9
Infective Endocarditis Associated with Implantable Cardiac Device by Metallo-β-Lactamase-Producing Pseudomonas aeruginosa, Successfully Treated with Source Control and Cefiderocol Plus Imipenem.产金属β-内酰胺酶的铜绿假单胞菌所致与植入式心脏装置相关的感染性心内膜炎，通过源头控制及头孢地尔联合亚胺培南成功治愈
Antimicrob Agents Chemother. 2023 Mar 16;67(3):e0131322. doi: 10.1128/aac.01313-22. Epub 2023 Feb 23.
10
The Role of Novel Antibiotics in the Management of Diabetic Foot Infection.新型抗生素在糖尿病足感染治疗中的作用
Diabetes Ther. 2023 Feb;14(2):251-263. doi: 10.1007/s13300-022-01357-2. Epub 2022 Dec 24.
Cefiderocol: a novel siderophore cephalosporin.
头孢地尔：一种新型铁载体头孢菌素。
Expert Opin Investig Drugs. 2018 Feb;27(2):193-197. doi: 10.1080/13543784.2018.1426745. Epub 2018 Jan 24.
4
Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study).头孢菌素类铁载体头孢地尔的活性对来自北美和欧洲的近期临床相关革兰氏阴性杆菌的收集，包括耐碳青霉烯类分离株（SIDERO-WT-2014 研究）。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00093-17. Print 2017 Sep.
5
Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment.头孢地尔，一种用于革兰氏阴性菌感染的铁载体头孢菌素：肾功能损害患者的药代动力学和安全性
J Clin Pharmacol. 2017 May;57(5):584-591. doi: 10.1002/jcph.841. Epub 2016 Nov 22.
6
Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function.用于基于肾功能进行剂量调整的肠外铁载体头孢菌素头孢地尔的药代动力学/药效学建模与模拟
Antimicrob Agents Chemother. 2016 Dec 27;61(1). doi: 10.1128/AAC.01381-16. Print 2017 Jan.
7
Non-nosocomial healthcare-associated left-sided Pseudomonas aeruginosa endocarditis: a case report and literature review.非医院获得性医疗保健相关左侧铜绿假单胞菌心内膜炎：一例报告及文献综述
BMC Infect Dis. 2016 Aug 20;16(1):431. doi: 10.1186/s12879-016-1757-y.
8
In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains.一种铁载体头孢菌素S-649266对肠杆菌科临床分离株（包括耐碳青霉烯菌株）的体外抗菌活性
Antimicrob Agents Chemother. 2015 Nov 16;60(2):729-34. doi: 10.1128/AAC.01695-15. Print 2016 Feb.
9
Endocarditis due to gram-negative bacilli at a French teaching hospital over a 6-year period: clinical characteristics and outcome.6 年间法国教学医院革兰氏阴性杆菌心内膜炎：临床特征和结局。
Infect Dis (Lond). 2015;47(12):889-95. doi: 10.3109/23744235.2015.1075660. Epub 2015 Aug 11.
10
The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.革兰氏阴性菌中由外排介导的抗生素耐药性挑战。
Clin Microbiol Rev. 2015 Apr;28(2):337-418. doi: 10.1128/CMR.00117-14.